- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Most Popular Stocks
U.S. Pharmaceuticals & Biotech Most Popular Stocks
Results
1140
Most Popular Stocks on the market
1140 companies
Whitehawk Therapeutics
Market Cap: US$89.1m
An oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
WHWK
US$1.94
7D
1.0%
1Y
0.5%
Coya Therapeutics
Market Cap: US$88.8m
A clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs).
COYA
US$5.49
7D
-0.2%
1Y
-18.8%
Immunic
Market Cap: US$88.6m
A biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
IMUX
US$0.94
7D
11.1%
1Y
-39.4%
Pliant Therapeutics
Market Cap: US$88.4m
A biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases.
PLRX
US$1.52
7D
6.3%
1Y
-86.6%
Champions Oncology
Market Cap: US$88.1m
A technology-enabled research company, provides technology solutions for drug discovery and development in the United States.
CSBR
US$6.30
7D
-4.0%
1Y
33.5%
Quince Therapeutics
Market Cap: US$87.6m
A biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
QNCX
US$1.61
7D
0.6%
1Y
101.3%
aTyr Pharma
Market Cap: US$87.5m
A clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
ATYR
US$0.84
7D
-15.3%
1Y
-52.5%
Lite Strategy
Market Cap: US$87.5m
A clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.
LITS
US$2.56
7D
-8.6%
1Y
-11.7%
InflaRx
Market Cap: US$87.4m
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
IFRX
US$1.30
7D
-3.0%
1Y
-17.2%
ImageneBio
Market Cap: US$87.0m
A clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases.
IMA
US$7.71
7D
-6.5%
1Y
n/a
Metagenomi
Market Cap: US$86.3m
A genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
MGX
US$2.29
7D
11.7%
1Y
3.2%
Nutriband
Market Cap: US$86.2m
Develops a portfolio of transdermal pharmaceutical products in the United States.
NTRB
US$7.26
7D
0.6%
1Y
20.8%
Assertio Holdings
Market Cap: US$85.2m
A pharmaceutical company, provides various products to patients in the United States.
ASRT
US$0.89
7D
-2.1%
1Y
-25.0%
BioStem Technologies
Market Cap: US$85.0m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
BSEM
US$4.97
7D
-3.8%
1Y
-50.3%
OKYO Pharma
Market Cap: US$83.5m
A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
OKYO
US$2.18
7D
10.1%
1Y
114.8%
Equillium
Market Cap: US$83.3m
A clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States.
EQ
US$1.50
7D
2.7%
1Y
80.2%
Vaxart
Market Cap: US$82.2m
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States.
VXRT
US$0.37
7D
-4.4%
1Y
-55.0%
XBiotech
Market Cap: US$82.0m
A biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases.
XBIT
US$2.70
7D
-0.7%
1Y
-62.6%
Entera Bio
Market Cap: US$81.7m
A clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs.
ENTX
US$1.82
7D
1.1%
1Y
-9.5%
MindWalk Holdings
Market Cap: US$81.7m
Operates as a bio-native AI company.
HYFT
US$1.80
7D
4.0%
1Y
178.0%
Context Therapeutics
Market Cap: US$81.0m
A biopharmaceutical company, develops products for the treatment of solid tumors.
CNTX
US$0.91
7D
-6.0%
1Y
-51.1%
Applied Therapeutics
Market Cap: US$80.7m
A clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States.
APLT
US$1.24
7D
185.3%
1Y
-85.0%
Coeptis Therapeutics Holdings
Market Cap: US$80.3m
Operates as a biopharmaceutical company.
COEP
US$17.50
7D
26.1%
1Y
414.1%
Sol-Gel Technologies
Market Cap: US$78.0m
Together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally.
SLGL
US$28.99
7D
-5.0%
1Y
326.4%
X4 Pharmaceuticals
Market Cap: US$75.9m
A biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
XFOR
US$3.46
7D
9.1%
1Y
-82.4%
PMV Pharmaceuticals
Market Cap: US$74.2m
A precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.
PMVP
US$1.48
7D
13.0%
1Y
-1.3%
Artiva Biotherapeutics
Market Cap: US$73.5m
A clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
ARTV
US$2.96
7D
2.8%
1Y
-78.9%
Sutro Biopharma
Market Cap: US$73.4m
Operates as a oncology company.
STRO
US$0.89
7D
0%
1Y
-74.7%
Nasus Pharma
Market Cap: US$72.9m
Operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.
NSRX
US$8.00
7D
-0.2%
1Y
n/a
CervoMed
Market Cap: US$72.4m
A a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
CRVO
US$8.28
7D
6.3%
1Y
-45.3%
Repare Therapeutics
Market Cap: US$71.7m
A clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States.
RPTX
US$1.69
7D
-1.2%
1Y
-50.9%
ABVC BioPharma
Market Cap: US$71.2m
A clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
ABVC
US$3.16
7D
11.3%
1Y
359.8%
Cibus
Market Cap: US$70.5m
An agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products.
CBUS
US$1.30
7D
-8.5%
1Y
-61.2%
Adicet Bio
Market Cap: US$69.8m
A clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
ACET
US$0.84
7D
5.7%
1Y
-41.3%
NRx Pharmaceuticals
Market Cap: US$69.2m
A clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain.
NRXP
US$2.95
7D
-0.7%
1Y
68.6%
Prelude Therapeutics
Market Cap: US$69.1m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$1.50
7D
52.3%
1Y
-29.2%